Curcumin suppresses TGF-β signaling by inhibition of TGIF degradation in scleroderma fibroblasts

Biochemical and Biophysical Research Communications

Volumn 411, Issue 4, 2011, Pages 821-825

  Song, Kemin ^a   Peng, Shaowen ^a   Sun, Zheng ^b   Li, Haitao ^a   Yang, Ronga ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Scleroderma fibroblasts; TGF ; TGIF

Indexed keywords

CURCUMIN; PROTEASOME; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SCLERODERMA; UBIQUITINATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CURCUMIN; FEMALE; FIBROBLASTS; HOMEODOMAIN PROTEINS; HUMANS; MIDDLE AGED; PHOSPHORYLATION; REPRESSOR PROTEINS; SCLERODERMA, SYSTEMIC; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

CURCUMA LONGA;

EID: 80051572060     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.044     Document Type: Article

References (27)

1. Yamamoto T. Scleroderma - pathophysiology. Eur. J. Dermatol. 2009, 19:14-24.
2. Leask A. Scar wars: is TGFbeta the phantom menace in scleroderma?. Arthritis Res. Ther. 2006, 8:213.
3. Feng X.H., Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 2005, 21:659-693.
4. Seo S.R., Lallemand F., Ferrand N., Pessah M., L'Hoste S., Camonis J., Atfi A. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J. 2004, 23:3780-3792.
5. Seo S.R., Ferrand N., Faresse N., Prunier C., Abecassis L., Pessah M., Bourgeade M.F., Atfi A. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol. Cell 2006, 23:547-559.
6. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 2007, 595:1-75.
7. Ahsan H., Parveen N., Khan N.U., Hadi S.M. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem. Biol. Interact. 1999, 121:161-175.
8. O'Connell M.A., Rushworth S.A. Curcumin: potential for hepatic fibrosis therapy?. Br. J. Pharmacol. 2008, 153:403-405.
9. Singh S., Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem. 2006, 6:259-270.
10. Shishodia S., Chaturvedi M.M., Aggarwal B.B. Role of curcumin in cancer therapy. Curr. Probl. Cancer 2007, 31:243-305.
11. Hu Y., Liang H., Du Y., Zhu Y., Wang X. Curcumin inhibits transforming growth factor-beta activity via inhibition of Smad signaling in HK-2 cells. Am. J. Nephrol. 2010, 31:332-341.
12. Hsu Y.C., Chen M.J., Yu Y.M., Ko S.Y., Chang C.C. Suppression of TGF-beta1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid. Arch. Dermatol. Res. 2010, 302:717-724.
13. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. RESEARCH0034.
14. Dennler S., Itoh S., Vivien D., Ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998, 17:3091-3100.
15. Yakymovych I., Ten Dijke P., Heldin C.H., Souchelnytskyi S. Regulation of Smad signaling by protein kinase C. FASEB J. 2001, 15:553-555.
16. Smith M.R., Gangireddy S.R., Narala V.R., Hogaboam C.M., Standiford T.J., Christensen P.J., Kondapi A.K., Reddy R.C. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. Am. J. Physiol.: Lung Cell. Mol. Physiol. 2010, 298:L616-L625.
17. Gaedeke J., Noble N.A., Border W.A. Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int. 2005, 68:2042-2049.
18. Reyes-Gordillo K., Segovia J., Shibayama M., Tsutsumi V., Vergara P., Moreno M.G., Muriel P. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam. Clin. Pharmacol. 2008, 22:417-427.
19. Punithavathi D., Venkatesan N., Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br. J. Pharmacol. 2000, 131:169-172.
20. Asano Y., Ihn H., Jinnin M., Tamaki K., Sato S. Altered dynamics of transforming growth factor beta (TGF-{beta}) receptors in scleroderma fibroblasts. Ann. Rheum. Dis. 2011, 70:384-387.
21. Kubo M., Ihn H., Yamane K., Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 2001, 44:731-734.
22. Kawakami T., Ihn H., Xu W., Smith E., LeRoy C., Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J. Invest. Dermatol. 1998, 110:47-51.
23. Gaedeke J., Noble N.A., Border W.A. Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int. 2004, 66:112-120.
24. Pessah M., Prunier C., Marais J., Ferrand N., Mazars A., Lallemand F., Gauthier J.M., Atfi A. c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc. Natl. Acad. Sci. USA 2001, 98:6198-6203.
25. Yang S., Nugent M.A., Panchenko M.P. EGF antagonizes TGF-beta-induced tropoelastin expression in lung fibroblasts via stabilization of Smad corepressor TGIF. Am. J. Physiol.: Lung Cell. Mol. Physiol. 2008, 295:L143-L151.
26. Bengoechea-Alonso M.T., Ericsson J. Tumor suppressor Fbxw7 regulates TGFbeta signaling by targeting TGIF1 for degradation. Oncogene 2010, 29:5322-5328.
27. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10:6847-6854.